Lupin’s US subsidiary - Lupin Pharmaceuticals Inc., has launched its Calcium Acetate Capsules, 667 mg (169 mg Calcium) having received final approval from the United States Food and Drug Administration (USFDA).
Lupin’s Calcium Acetate Capsules, 667 mg (169 mg Calcium) are the AB rated generic equivalent of Fresenius Medical Care North America’s (Fresenius) PhosLo Gelcaps 667 mg (169 mg Calcium) and are indicated for the control of hyperphosphatemia in end stage renal failure. PhosLo Gelcaps had annual US sales of $54.5 million, as per IMS MAT March, 2015.
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.
